Skip to Main Content

Paper Details

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.
Haematologica
14
2022
BRAF, COP9 signalosome complex, COPS3, EWSR1, HCFC2, IMiD, MLLT4, MM, NRAS, PARP, RRMM, SLC4A7, TP53, genomic regions, melphalan, multiple myeloma, patients, recurrently mutated gene networks, refractory, therapeutic, tumor, tumor suppressor genes
Author NameAffiliation
Nagarajan ParamasivamGerman Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ) Heidelberg
Sebastian UhrigNational Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ) Heidelberg, German Cancer Research Center (DKFZ)
Benedikt BrorsGerman Cancer Research Center (DKFZ), Germany National Center for Tumor Diseases (NCT)
Benedikt BrorsGerman Cancer Research Center (DKFZ), Germany National Center for Tumor Diseases (NCT)
Niels WeinholdHeidelberg University Hospital
Matthias SchlesnerGerman Cancer Research Center (DKFZ)
Matthias SchlesnerGerman Cancer Research Center (DKFZ)
  • 1 - 7

Datasets

Release 1.2